3-(4-Hydroxymethylbenzoyl)-1-pentylindole is classified as a synthetic cannabinoid, and there are plans to include it in Schedule I-N in Poland. This compound was first reported to the EMCDDA and Europol in 2010 by the provisions of the European Council Decision 2005/387/JHA dated 10 May 2005, which pertains to the exchange of information, risk assessment, and control of new psychoactive substances.
|3D model (JSmol)||Interactive image|
1. What is 3-(4-Hydroxymethylbenzoyl)-1-pentylindole?
3-(4-Hydroxymethylbenzoyl)-1-pentylindole is a synthetic cannabinoid, a class of compounds designed to interact with the endocannabinoid system like naturally occurring cannabinoids.
2. Why is this compound of interest?
It is interesting due to its potential psychoactive properties and has garnered attention from regulatory bodies in some regions.
3. What is the scheduling status in Poland?
There are plans to schedule 3-(4-Hydroxymethylbenzoyl)-1-pentyl indole in Poland, specifically in Schedule I-N. This implies stricter control and regulation.
4. When was it first reported to EMCDDA and Europol?
This compound was first reported to the EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) and Europol in 2010.
5. What prompted its reporting to these agencies?
The reporting of 3-(4-Hydroxymethylbenzoyl)-1-pentylindole complied with European Council Decision 2005/387/JHA, which outlines the procedures for sharing information, conducting risk assessments, and controlling new psychoactive substances.
6. Is this compound commonly used or found in recreational products?
The prevalence of 3-(4-Hydroxymethylbenzoyl)-1-pentylindole in recreational products may vary by region, and its use is often associated with the evolving landscape of synthetic cannabinoids.
7. What are the potential risks associated with this compound?
The potential risks are still being explored, and research on its effects and safety profile is ongoing. The scheduling of the compound in certain regions suggests regulatory concerns.
8. Can individuals legally obtain or use this compound?
The legal status of 3-(4-Hydroxymethylbenzoyl)-1-pentylindole varies by country and region. It is crucial to be aware of and comply with local laws and regulations.
9. Where can I find more information about 3-(4-Hydroxymethylbenzoyl)-1-pentylindole?
To delve deeper into the compound and its regulatory status, you can refer to official sources such as government health agencies, drug control authorities, or relevant scientific publications. Always prioritize reliable and up-to-date information.
- In a document from the Polish Ministry of Health, an expert assessment conducted by the Department of Experimental and Clinical Pharmacology at the Medical University of Warsaw supported the legal regulation of synthetic cannabinoids. Specifically, it recommended the control of JWH-015, JWH-098, JWH-251, JWH-307, AM-2201, and 3-(4-hydroxymethylbenzoyl)-1-pentylindole.
- The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) compiled a list of new psychoactive substances reported for the first time in 2010 under the provisions of European Council Decision 2005/387/JHA. This document provides insights into the regulation and control of emerging psychoactive substances.
- European Council Decision 2005/387/JHA, dated 10 May 2005, outlines the procedures for information exchange, risk assessment, and control of new psychoactive substances. It serves as a fundamental framework for managing and regulating these substances.